BRCA2 and neoplasm: Another 41 young patients, aged ≤35 years, had their tumor samples evaluated for the presence of somatic mutations in PIK3CA. This is a subgroup of patients whose clinical data, as well as germline BRCA1 and BRCA2 sequencing results had already been reported in a previous study (22).